Top Industrial Disributor Companies To Own In Right Now

Indian Prime Minister Manmohan Singh is hoping developed economies will ensure their exit from stimulus programs will be "orderly."

LONDON (CNNMoney) The world's biggest emerging markets pledged Friday to create a $100 billion fund to help protect their economies from shocks as G20 leaders warned that the global recovery was still at risk from volatile capital flows.

According to the agreement announced at the meeting of G20 leaders in Russia, China will contribute $41 billion to the fund. Brazil, Russia and India will provide $18 billion each while new BRIC member South Africa will pay $5 billion.

The fund -- dubbed the Contingent Reserve Arrangement -- is designed to provide member countries with an emergency cushion of cash during times of crisis. Its creation reflects frustration in emerging markets at a lack of influence over institutions such as the International Monetary Fund despite their growing importance in the world economy.

Top China Companies To Invest In 2015: Dendreon Corporation(DNDN)

Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients. The company offers active cellular immunotherapy and small molecule product candidates to treat various cancers. Its product candidates comprise Provenge (sipuleucel-T), an active cellular immunotherapy for the treatment of metastatic, castrate-resistant prostate cancer; DN24-02, an investigational active immunotherapy for the treatment of patients with bladder, breast, ovarian, and other solid tumors expressing HER2/neu; and TRPM8, a small molecule agonist to transient receptor potential ion channel, for multiple cancers. The company also has a range of products in preclinical studies, which include Carcinoembryonic antigen for the treatment of lung, colon, and breast cancer; and Carbonic AnhydraseIX for the treatment of kidney cancer. Dendreon Corporation was founded in 1992 and is headquartered in S eattle, Washington.

Advisors' Opinion:

• [By Bryan Murphy]

  It may not have blazed a trail into the young, immunology segment of the biotech industry the way Dendreon Corporation (NASDAQ:DNDN) did back in 2010 with the debut of Provenge. It may not have the same immunology pipeline (and company size) that ImmunoGen, Inc. (NASDAQ:IMGN) boasts. One thing is pretty certain about cancer-immunotherapy developer CEL-SCI Corporation (NYSEMKT:CVM) right now, however - its stock may be poised to dole out a much bigger foreseeable-future reward than DNDN or IMGN are.

• [By Johanna Bennett]

  Once, one of the hottest biotech stocks around, Dendreon (DNDN) has become a cautionary tale, warning investors what can happen when a cutting-edge�drug turns into a dud.

  Now at less than $3 a share, the stock had traded as high as $54 in 2010 as excitement buzzed over the�experimental prostate cancer vaccine Provenge. Initially, Wall Street expected peak sales of $3 billion to $4 billion. But insurers balked at the�hefty price tag for Provenge, and now, three years after it�won FDA approval, analysts see annual sales at roughly $300 million.

  Disappointing sales are just one reason Deutsche Bank has joined the�bearish�voices surrounding this drug maker.�Today, analyst Robyn Karnauskas downgraded Dendreon�to a Sell and cut the�price target to $1, warning that even if the company�can significantly reduce�costs and drastically restructures, its�spending may still outpace revenue growth in the short-term. Karnauskas believes Dendreon may have to refinance its debt, negatively impacting shareholders.

  Earlier this month, the company�posted a bigger-than-expected second-quarter loss as Provenge sales fell compared to last year. A restructuring plan was�unveiled in late July, though�analysts say it isn’t enough without revenue growth.�Today, Deutsche Bank’s Karnauskas writes:�

  …By our math, even with $165M in cost cuts, the co will have to grow current sales from $300M to $525M over next 7 years to support current share price. 2Q13 sales were $73M and DTC campaign does not seem to have a lot of effect to offset impact from competition so that the company could reach profitability in 4Q13. While they note that they plan to cut costs, we are concerned it may be too late. Revenue growth is not occurring quick enough; we note 1Q13 yoy growth was guided and in 2Q13 they noted this was unlikely to occur going fwd. The co�� inability to guide growth & provide visibility makes it difficult for us to see sales a

• [By Keith Speights]

  3. Dendreon (NASDAQ: DNDN  )
  If the 10-year period we were looking at ended in 2011, Dendreon would come out looking really good. For the last decade, though, that's not the case at all. Shares slumped 26% over the past 10 years.

Top Industrial Disributor Companies To Own In Right Now: GTx Inc.(GTXI)

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions. The company markets FARESTON (toremifene citrate) 60 mg tablets for the treatment of metastatic breast cancer in postmenopausal women primarily through wholesale drug distributors in the United States. It is developing selective androgen receptor modulators (SARMs), including Ostarine (GTx-024), which has completed Phase II clinical trial for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer; and CapesarisTM (GTx-758), a selective estrogen receptor alpha agonist that has completed Phase IIa clinical trial for the first line treatment of advanced prostate cancer. In addition, the company is developing estrogen receptor beta agonists and other novel compounds that are in preclinical development stage for the treatment of metabo lic diseases, ophthalmic diseases, cancer, psoriasis, and/or pain. The company was founded in 1997 and is headquartered Memphis, Tennessee.

Advisors' Opinion:

• [By Paul Ausick]

  GTX Inc. (NASDAQ: GTXI) is down 66.9% at $1.38 after posting a new 52-week low of $1.31 earlier today. The biopharmaceutical maker�� shares collapsed on news of a failed trial for its muscle drug.

• [By Roberto Pedone]

  One biopharmaceutical player that's rapidly moving within range of triggering a major breakout trade is GTx (GTXI), which is dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle loss and other serious medical condition. This stock has been hammered by the bears so far in 2013, with shares off sharply by 53%.

  If you look at the chart for GTx, you'll notice that this stock recently gapped down sharply from over $4 to below $1.50 a share with heavy downside volume. Following that gap down, shares of GTXI have rebounded sharply and started to uptrend, with the stock moving higher from its low of $1.31 to its recent high of $1.96 a share. During that move, shares of GTXI have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of GTXI within range of triggering a major breakout trade.

  Traders should now look for long-biased trades in GTXI if it manages to break out above some near-term overhead resistance at $1.96 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.35 million shares. If that breakout triggers soon, then GTXI will set up to re-fill some of its previous gap down zone from August that started just above $4 a share. Some possible upside targets if GTXI gets into that gap with volume are $2.50 to $3 a share, or possibly even $3.50 a share.

  Traders can look to buy GTXI off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support at $1.50 a share. One can also buy GTXI off strength once it takes out $1.96 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Keith Speights]

  War of words
  In the stock market, the old saying that "sticks and stones may break my bones, but words can never hurt me" doesn't hold water. GTx (NASDAQ: GTXI  ) investors experienced that reality firsthand this week, with shares dropping 15% from an online article published on Wednesday.

Top Industrial Disributor Companies To Own In Right Now: Pactera Technology International Ltd (PACT)

Pactera Technology International Ltd. (Pactera), formerly HiSoft Technology International Limited, incorporated on May 27, 2004, provides global consulting and technology services. The Company provides business/information technology (IT) consulting, solutions, and outsourcing services to a range of multinational firms through a globally integrated network of onsite and offsite delivery locations in China, the United States, Europe, Australia, Japan, Singapore and Malaysia. In January 2014, Pactera Technology International Ltd announced the acquisition of Innoveo Solutions AG.

The Company�� services include business and technology advisory, enterprise application services, business intelligence, application development and maintenance, mobility, cloud computing, infrastructure management, software product engineering and globalization, and business process outsourcing. The Company�� clients include 3M, ABB, Cathay Pacific, China Merchants Bank, Citibank, EMC, Expedia, GE, HP, IBM, Lenovo, Microsoft, Mitsubishi, NEC and TIBCO.

Advisors' Opinion:

• [By Seth Jayson]

  Pactera Technology International (Nasdaq: PACT  ) reported earnings on May 23. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended March 31 (Q1), Pactera Technology International missed estimates on revenues and met expectations on earnings per share.

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Pactera Technology International (Nasdaq: PACT  ) , whose recent revenue and earnings are plotted below.

Top Industrial Disributor Companies To Own In Right Now: Analog Devices Inc (ADI)

Analog Devices, Inc. (Analog Devices), incorporated on January 18, 1965, is engaged in the design, manufacture and marketing of a range of analog, mixed-signal and digital signal processing integrated circuits (ICs). The Company produces a range of products, including data converters, amplifiers and linear products, radio frequency (RF) ICs, power management products, sensors based on micro-electro mechanical systems (MEMS) technology and other sensors, and processing products, including DSP and other processors, which are designed to meet the needs of a base of customers. The Company's products are embedded inside many different types of electronic equipment, including industrial process control systems; instrumentation and measurement systems; wireless infrastructure equipment, and aerospace and defense electronics. The Company designs , manufactures and markets a range of ICs, which incorporate analog, mixed-signal and digital signal processing technologies. The Company's product portfolio includes both general-purpose products used by a range of customers and applications, as well as application-specific products. On March 30, 2012, the Company acquired Multigig, Inc.

Analog Products

The Company's product portfolio includes several thousand analog ICs. The Company's analog IC customers include original equipment manufacturers (OEMs) and customers who build electronic subsystems for integration into larger systems. The Company is a supplier of data converter products. Data converters translate real-world analog signals into digital data and also translate digital data into analog signals. The Company is also a supplier of amplifiers. Amplifiers are used to condition analog signals. The Company provides precision, instrumentation, intermediate frequency/radio frequency (RF), broadband, and other amplifiers. The Company also offers a range of precision voltage references, which are used in a range of applications. The Company's analog product line also includes a range port! folio of RF ICs covering the RF signal chain, from RF function blocks, such as phase locked loops, frequency synthesizers, mixers, modulators, demodulators, and power detectors, to broadband and short-range single chip transceiver solutions.

The Company's RF ICs support the requirements of cellular infrastructure and a range of applications in the Company's target markets. Also within the Company's analog technology portfolio are products, which are based on MEMS technology. This technology enables the Company to build small sensors, which incorporate an electromechanical structure and the supporting analog circuitry for conditioning signals obtained from the sensing element. The Company's MEMS product portfolio includes accelerometers used to sense acceleration, gyroscopes used to sense rotation, inertial measurement units used to sense multiple degrees of freedom combining multiple sensing types along multiple axis, and MEMS microphones used to sense audio. The Company's current revenue from MEMS products is derived from the automotive end market. In addition to the Company's MEMS products, its other analog product category includes isolators. The Company's isolators have been designed for applications, such as universal serial bus isolation in patient monitors, where it allows hospitals and physicians to adopt the advances in computer technology to supervise patient health and wirelessly transmit medical records. In smart metering applications, the Company's isolators provide electrostatic discharge performance. In satellites, where any malfunction can be catastrophic, the Company's isolators help protect the power system while enabling designers to achieve small form factors. Power management & reference products make up the balance of the Company's analog sales. Those products, which include functions such as power conversion, driver monitoring, sequencing and energy management, are developed to complement analog signal chain components across core market segments from micro power, en! ergy-sens! itive battery applications to power systems in infrastructure and industrial applications.

Digital Signal Processing Products

Digital Signal Processing products (DSPs) complete the Company's product portfolio. DSPs are optimized for numeric calculations, which are essential for instantaneous, or real-time, processing of digital data generated, from analog to digital signal conversion. The Company's DSPs are designed to be fully programmable and to execute specialized software programs, or algorithms, associated with processing digitized real-time, real-world data. Programmable DSPs are designed to provide the flexibility to modify the device's function using software. The Company's DSP IC customers write their own algorithms using software development tools provided by the Company and third-party suppliers. The Company's DSPs are designed in families of products, which share common architectures and therefore can execute the same software across a range of products. The Company's customers use the Company's products to solve a range of signal processing challenges across its core market and segment focus areas within the industrial, automotive, consumer and communications end markets. As an integrated part of the Company's customers' signal chain, there are other Analog Devices products connected to its processors, including converters, audio and video codecs and power management solutions.

The Company competes with Broadcom Corporation, Maxim Integrated Products, Inc., Cirrus Logic, Inc., Microchip Technology, Inc., Freescale Semiconductor, Inc., NXP Semiconductors, Infineon Technologies, ST Microelectronics, Intersil Corporation, Silicon Laboratories, Inc., Knowles Electronics, Texas Instruments, Inc. and Linear Technology Corporation.

Advisors' Opinion:

• [By Ben Eisen and Saumya Vaishampayan]

  Analog Devices Inc. (ADI) �sank nearly 3%. The semiconductor firm reported late Tuesday fourth-quarter adjusted earnings of 62 cents a share and sales of $678 million, with sales missing analyst expectations.

• [By Laura Brodbeck]

  Earnings Expected: From�Barnes & Noble, Inc. (NYSE: BKS), DSW Inc. (NYSE: DSW), Tiffany & Co., Hormel Foods Corporation (NYSE: HRL), TiVo Inc., Analog Devices, Inc. (NASDAQ: ADI), Hewlett-Packard Company.